Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 191-201

  Quach, Alekist ^a   Ji, Lingyun ^b   Mishra, Vikash ^a   Sznewajs, Aimee ^a   Veatch, Janet ^a   Huberty, John ^c   Franc, Benjamin ^c   Sposto, Richard ^b,d   Groshen, Susan ^d   Wei, Denice ^d   Fitzgerald, Paul ^a   Maris, John M ^e,f   Yanik, Gregory ^g   Hawkins, Randall A ^c   Villablanca, Judith G ^b   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

131I MIBG; Hypothyroidism; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; AMINOTRANSFERASE; IRINOTECAN; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; VINCRISTINE;

ARTICLE; CANCER PATIENT; CANCER RELAPSE; CHILD; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; LIVER FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; SYMPTOM; THYROID FUNCTION; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIVER; LIVER FUNCTION TESTS; MALE; NEUROBLASTOMA; THYROID GLAND; YOUNG ADULT;

EID: 78650143642     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22767     Document Type: Article

References (39)

1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J Clin Oncol 2009; 27: 1007-1013.
2. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007; 25: 1054-1060.
3. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer 1999; 81: 1378-1384.
4. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236.
5. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992; 10: 1889-1896.
6. Voute PA, Hoefnagel CA, de Kraker J, et al. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 1991; 366: 439-445.
7. Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: A phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991; 35: 220-223.
8. Klingebiel T, Feine U, Treuner J, et al. Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: Long-term results in 25 patients. J Nucl Biol Med 1991; 35: 216-219.
9. Hutchinson RJ, Sisson JC, Miser JS, et al. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 1991; 35: 237-240.
10. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008; 35: S35-S48.
11. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24: 500-506.
12. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 2142-2149.
13. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998; 34: 1398-1402.
14. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460-464.
15. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005; 20: 195-199.
16. Hoefnagel CA, De Kraker J, Valdes Olmos RA, et al. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 1994; 15: 712-717.
17. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004; 22: 2452-2460.
18. Hoefnagel CA, Voute PA, De Kraker J, et al. [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 1991; 35: 202-206.
19. van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41: 1767-1774.
20. van Santen HM, de Kraker J, van Eck BL, et al. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 2003; 98: 389-396.
21. van Santen HM, de Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94: 2081-2089.
22. Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995; 76: 1662-1664.
23. Brans B, Monsieurs M, Laureys G, et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: Influence of potassium iodide for thyroid blocking. Med Pediatr Oncol 2002; 38: 41-46.
24. Modak S, Pandit-Taskar N, Kushner BH, et al. Transient sialoadenitis: A complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 2008; 50: 1271-1273.
25. Weiss B, Vora A, Huberty J, et al. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003; 25: 543-547.
26. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2003; 97: 1332-1338.
27. Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27: 1020-1025.
28. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42: 1713-1721.
29. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-565.
30. Cox DRaDO. Analysis of survival data. New York: Chapman and Hall; 1984.
31. StataCorp. "Stata Statistical Software" Release 9. 2005. College Station, TX: StataCorp. LP; 2005.
32. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 2006; 12: 1750-1759.
33. Wafelman AR, Hoefnagel CA, Maes RA, et al. Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion. Nuklearmedizin 1996; 35: 122-125.
34. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: An update. J Endocrinol 2010; 205: 1-13.
35. Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 2003; 97: 2397-2403.
36. Papadopoulou F, Efthimiou E. Thyroid cancer after external or internal ionizing irradiation. Hell J Nucl Med 2009; 12: 266-270.
37. Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682.
38. Jacobsson LMS, Johansson L, Lindberg S, et al. Biokinetics and dosimetry of 131-I-metaiodobenzylguanidine (MIBG). Proceeding of Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN; 1985.
39. Koral KF, Huberty JP, Frame B, et al. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging 2008; 35: 2105-2112.